Oryzon Genomics financials at a glance

The revenue of Oryzon Genomics is reported as 0 billion Euro in the fiscal year 2023. The earnings were -0.06 Euro per share in 2023, which was 11.11 higher than 2021. And about -0.00017 billion Euro are reported as free cash flow in the financials of Oryzon Genomics 2023. No dividends were paid to the shareholders of the Oryzon Genomics stock BME:ORY in the financial year 2023.